BOSTON ( TheStreet) -- Welcome to December's Biotech Stock Mailbag Live Chat. The floor is yours. I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing. Is there any hope for BioSante Pharma's ( BPAX) future after the Libigel blow up? What about Antares Pharma ( AIS) -- is it also mortally wounded? Vertex Pharmaceuticals ( VRTX) announced a CEO swap this morning Surprised? Does this signal more changes in store for the company as it transitions from a focus on hepatitis C to cystic fibrosis? We can talk about YM BioSciences ( YMI) and what lies ahead after this week's presentation of strong data on the myelofibrosis drug CYT387. Can YM Bio's market cap catch up to that of rival Incyte ( INCY)? Were you confused by this week's Alexza Pharmaceuticals ( ALXA) FDA panel? Me too, but let's hash out the future for Adasuve. The year is almost over, so it's time to look ahead to key biotech events in 2012, including results from late-stage cancer immunotherapy trials involving Oncothyreon ( ONTY) and Vical ( VICL). And let's not forget that obesity drug stocks Arena Pharma ( ARNA) and Vivus ( VVUS) should be volatile again in 2012. Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.